Chondrosarcoma diagnostic study of choice: Difference between revisions
(Created page with "__NOTOC__ {{Chondrosarcoma}} {{CMG}}; {{AE}} == Overview == == Diagnostic Study of Choice == === Study of choice === [Name of the investigation] is the gold standard test fo...") |
No edit summary |
||
Line 81: | Line 81: | ||
* [2nd investigation] | * [2nd investigation] | ||
=== | ===Enneking (MSTS) Staging System=== | ||
*The Enneking surgical staging system (also known as the MSTS system) for malignant [[Musculoskeletal system|musculoskeletal]] [[Tumor|tumors]] based on histological and [[radiographic]] characteristics of the tumor host margin.<ref name="pmid20333492">{{cite journal| author=Jawad MU, Scully SP| title=In brief: classifications in brief: enneking classification: benign and malignant tumors of the musculoskeletal system. | journal=Clin Orthop Relat Res | year= 2010 | volume= 468 | issue= 7 | pages= 2000-2 | pmid=20333492 | doi=10.1007/s11999-010-1315-7 | pmc=2882012 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20333492 }} </ref><ref>{{cite book | last = Peabody | first = Terrance | title = Orthopaedic oncology : primary and metastatic tumors of the skeletal system | publisher = Springer | location = Cham | year = 2014 | isbn = 9783319073224 }}</ref> | |||
*It is widely accepted and routinely used staging system. | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center" | |||
| valign="top" | | |||
|- | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Stages}} | |||
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Grade}} | |||
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Site}} | |||
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Metastasis}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |IA | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | G1: Low grade | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | T1: Intracompartmental | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | M0: No metastasis | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |IB | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | G1: Low grade | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | T2: Extracompartmental | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | M0: No metastasis | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |IIA | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | G2: High grade | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | T1: Intracompartmental | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | M0: No metastasis | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |IIB | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | G2: High grade | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | T2: Extracompartmental | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | M0: No metastasis | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |III | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | G1 or G2 | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | T1 or T2 | |||
| style="padding: 5px 5px; background: #F5F5F5; font-weight: bold; text-align:center;" | M1: Regional or distant metastasis | |||
|} | |||
==References== | ==References== | ||
Line 130: | Line 123: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: Orthopedics]] | |||
[[Category: Oncology]] | |||
[[Category: Up-To-Date]] |
Revision as of 04:55, 23 January 2019
Chondrosarcoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Chondrosarcoma diagnostic study of choice On the Web |
American Roentgen Ray Society Images of Chondrosarcoma diagnostic study of choice |
Risk calculators and risk factors for Chondrosarcoma diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Diagnostic Study of Choice
Study of choice
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The following result of [gold standard test] is confirmatory of [disease name]:
- [Result 1]
- [Result 2]
OR
[Name of the investigation] must be performed when:
- The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
- A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.
OR
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
OR
The diagnostic study of choice for [disease name] is [name of the investigation].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name].
OR
There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
OR
[Disease name] is primarily diagnosed based on the clinical presentation.
OR
Investigations:
- Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
- Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
- Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.
The comparison of various diagnostic studies for [disease name]
Test | Sensitivity | Specificity |
---|---|---|
Test 1 | ...% | ...% |
Test 2 | ...% | ...% |
[Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity
Diagnostic results
The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:
- [Finding 1]
- [Finding 2]
Sequence of Diagnostic Studies
The [name of investigation] must be performed when:
- The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
- A positive [test] is detected in the patient, to confirm the diagnosis.
OR
The various investigations must be performed in the following order:
- [Initial investigation]
- [2nd investigation]
Enneking (MSTS) Staging System
- The Enneking surgical staging system (also known as the MSTS system) for malignant musculoskeletal tumors based on histological and radiographic characteristics of the tumor host margin.[1][2]
- It is widely accepted and routinely used staging system.
Stages | Grade | Site | Metastasis |
---|---|---|---|
IA | G1: Low grade | T1: Intracompartmental | M0: No metastasis |
IB | G1: Low grade | T2: Extracompartmental | M0: No metastasis |
IIA | G2: High grade | T1: Intracompartmental | M0: No metastasis |
IIB | G2: High grade | T2: Extracompartmental | M0: No metastasis |
III | G1 or G2 | T1 or T2 | M1: Regional or distant metastasis |
References
- ↑ Jawad MU, Scully SP (2010). "In brief: classifications in brief: enneking classification: benign and malignant tumors of the musculoskeletal system". Clin Orthop Relat Res. 468 (7): 2000–2. doi:10.1007/s11999-010-1315-7. PMC 2882012. PMID 20333492.
- ↑ Peabody, Terrance (2014). Orthopaedic oncology : primary and metastatic tumors of the skeletal system. Cham: Springer. ISBN 9783319073224.